"[Novartis, Amgen and Lilly are] developing medicines that lower the level of lipoprotein(a), a fatty particle in the blood that is known as Lp(a)... Tens of millions of people in the U.S. have elevated Lp(a), an inherited and largely hidden driver of heart disease."
www.wsj.com/health/pharm...
